1201 related articles for article (PubMed ID: 16875636)
21. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
Clark JI; Kancharla K; Qamar R; Fisher S; Hantel A; Panganiban J; Millbrandt L; Albain KS
Lung Cancer; 2001 Nov; 34(2):271-7. PubMed ID: 11679186
[TBL] [Abstract][Full Text] [Related]
22. Multicenter Phase II Study Evaluating Two Cycles of Docetaxel, Cisplatin and Cetuximab as Induction Regimen Prior to Surgery in Chemotherapy-Naive Patients with NSCLC Stage IB-IIIA (INN06-Study).
Hilbe W; Pall G; Kocher F; Pircher A; Zabernigg A; Schmid T; Schumacher M; Jamnig H; Fiegl M; Gächter A; Freund M; Kendler D; Manzl C; Zelger B; Popper H; Wöll E
PLoS One; 2015; 10(5):e0125364. PubMed ID: 26020783
[TBL] [Abstract][Full Text] [Related]
23. Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study.
Pérol M; Léna H; Thomas P; Robinet G; Fournel P; Coste E; Belleguic C; Le Caer H; Blanchon F; Vergnenègre A; Vernejoux JM; Schuller-Lebeau MP; Pham E
Ann Oncol; 2002 May; 13(5):742-7. PubMed ID: 12075743
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer.
Kaira K; Takise A; Minato K; Iwasaki Y; Ishihara S; Takei Y; Tsuchiya S; Saito R; Sato K; Mori M
Anticancer Drugs; 2005 Apr; 16(4):455-60. PubMed ID: 15746583
[TBL] [Abstract][Full Text] [Related]
25. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of cisplatin and docetaxel plus mitomycin C in patients with metastatic non-small cell lung cancer.
Hosomi Y; Ohe Y; Mito K; Uramoto H; Moriyama E; Tanaka K; Kodama K; Niho S; Goto K; Ohmatsu H; Matsumoto T; Hojo F; Kakinuma R; Nishiwaki Y
Jpn J Clin Oncol; 1999 Nov; 29(11):546-9. PubMed ID: 10678557
[TBL] [Abstract][Full Text] [Related]
27. Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer.
Hamada H; Irifune K; Ito R; Sakai K; Kadowaki T; Katayama H; Abe M; Shiode M; Nishimura K; Higaki J
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1235-9. PubMed ID: 17687204
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer.
Mattson K; Vansteenkiste J; Stupp R; Bargetzi M; Saarinen A; Jekunen A; Fillet G; Teixeira M; Gatzemeier U; Olivares R; Soussan-Lazard K; Bérille J
Anticancer Drugs; 2000 Jan; 11(1):7-13. PubMed ID: 10757557
[TBL] [Abstract][Full Text] [Related]
29. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).
Gervais R; Ducolone A; Breton JL; Braun D; Lebeau B; Vaylet F; Debieuvre D; Pujol JL; Tredaniel J; Clouet P; Quoix E
Ann Oncol; 2005 Jan; 16(1):90-6. PubMed ID: 15598944
[TBL] [Abstract][Full Text] [Related]
30. A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
Grossi F; de Marinis F; Gebbia V; Riccardi F; Caffo O; Gamucci T; Ferraù F; Nardi M; Moscetti L; Boni L; Dondi D; Galligioni E
Cancer Chemother Pharmacol; 2012 Feb; 69(2):369-75. PubMed ID: 21833588
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS
Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
[TBL] [Abstract][Full Text] [Related]
32. [Phase I study of docetaxel combined with carboplatin in patients with non-small cell lung cancer].
Zhu LM; Li QY; Yu XM; Ma SL
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):946-8. PubMed ID: 17533750
[TBL] [Abstract][Full Text] [Related]
33. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of weekly docetaxel-cisplatin as first-line treatment for advanced non-small cell lung cancer.
Binder D; Hackenthal M; Graseck L; Schweisfurth H; Schäper C; Krüll M; Temmesfeld-Wollbrück B; Suttorp N; Beinert T; Hellriegel KP
J Thorac Oncol; 2009 Sep; 4(9):1144-7. PubMed ID: 19609222
[TBL] [Abstract][Full Text] [Related]
35. A phase I study of weekly docetaxel and cisplatin in advanced non-small cell lung cancer.
Sato K; Tsuchiya S; Minato K; Takei Y; Watanabe S; Saitoh R; Mori M
Lung Cancer; 2001 Jul; 33(1):69-73. PubMed ID: 11429197
[TBL] [Abstract][Full Text] [Related]
36. Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L.
Abe T; Takeda K; Ohe Y; Kudoh S; Ichinose Y; Okamoto H; Yamamoto N; Yoshioka H; Minato K; Sawa T; Iwamoto Y; Saka H; Mizusawa J; Shibata T; Nakamura S; Ando M; Yokoyama A; Nakagawa K; Saijo N; Tamura T
J Clin Oncol; 2015 Feb; 33(6):575-81. PubMed ID: 25584004
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
Kim YH; Kim JS; Choi YH; In KH; Park HS; Hong DS; Jeong TJ; Lee YY; Nam E; Lee SN; Lee KS; Kim HK
Int J Clin Oncol; 2002 Apr; 7(2):114-9. PubMed ID: 12018108
[TBL] [Abstract][Full Text] [Related]
38. A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study.
Tabata M; Kozuki T; Ueoka H; Kiura K; Harita S; Tada A; Shibayama T; Takigawa N; Yonei T; Gemba K; Segawa Y; Kishino D; Tada S; Hiraki S; Tanimoto M;
Cancer Chemother Pharmacol; 2007 Jun; 60(1):53-9. PubMed ID: 17009034
[TBL] [Abstract][Full Text] [Related]
39. Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer.
Yamamoto N; Nishimura Y; Nakagawa K; Matsui K; Fukuoka M
Cancer Chemother Pharmacol; 2006 Sep; 58(3):285-91. PubMed ID: 16416334
[TBL] [Abstract][Full Text] [Related]
40. Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients.
Ohe Y; Niho S; Kakinuma R; Kubota K; Matsumoto T; Ohmatsu H; Goto K; Kunitoh H; Saijo N; Nishiwaki Y
Jpn J Clin Oncol; 2001 Mar; 31(3):100-6. PubMed ID: 11336320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
